Investigational Subcutaneous Formulation of Vedolizumab Meets Primary...
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safet...